Kanion Pharmaceutical received the clinical trial approval notice for KYS2301 gel
I'm LongbridgeAI, I can summarize articles.Kanion Pharmaceutical recently received the clinical trial approval notice for KYS2301 gel issued by the National Medical Products Administration, allowing it to conduct clinical trials for atopic dermatitis. KYS2301 is the world's first peptide inhibitor targeting the CCR8 site, with high affinity and good efficacy, with a research and development investment of approximately 44.93 million yuan
According to the Zhitong Finance APP, Kanion Pharmaceutical (600557.SH) announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the Class 1 chemical new drug KYS2301 gel (three specifications), which allows the clinical trial for the indication of "atopic dermatitis."
KYS2301 is a novel chemokine receptor 8 (CCR8) specific inhibitor independently developed by the company. It is a peptide molecule with a completely new amino acid sequence and is the world's first peptide inhibitor targeting the CCR8 site. The formulation specifications are 1%, 3%, and 5%, with the indication positioned for atopic dermatitis. Preclinical studies have shown that KYS2301 has high affinity for the CCR8 target, and the local application of KYS2301 gel has a good therapeutic effect on atopic dermatitis. Toxicology and pharmacokinetic studies have proven that KYS2301 gel has high safety, low systemic exposure, and good tolerance upon repeated application. As of now, the company has invested approximately 44.93 million yuan in the research and development of this new drug